IP Library Granted Patent US 7,273,619
Granted Patent B2
US 7,273,619 · App. 10/414,827 · Granted Sep 25, 2007

Transdermal composition of an antivomiting agent

Assignee: Samyang Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,273,619
App. No.
10/414,827
Granted
Sep 25, 2007
Kind
B2
Abstract

The present invention relates to a transdermal composition of an antivomiting agent, and more particularly to a transdermal composition of an antivomiting agent which can minimize skin irritation by employing tropisetron as the antivomiting agent as well as by adjusting its pH to be in the range of 8 to 9 thus enhancing its rate of skin penetration thereby reducing the amount of a skin penetration enhancer used.

Claims (32)

1. A transdermal composition of an antivomiting agent comprising:

(a) 96 to 98 wt % of a vehicle for transdermal delivery comprising

(i) 25 to 45 wt % of a mixed solution comprising ethanol and propylene glycol,

(ii) a skin penetration enhancer containing 0.5 to 1.5 wt % of a fatty acid ester, and 2 to 5 wt % of an amide compound,

(iii) 50 to 70 wt % of a borate buffer solution; and

(b) 2 to 4 wt % of a pharmaceutically acceptable salt of tropisetron as an antivomiting agent, wherein the pH of said composition is within the range of 8 to 9.

2. The transdermal composition according to claim 1 , wherein said transdermal composition has a pH in the range of 8 to 8.5.

3. The transdermal composition according to claim 1 , wherein said fatty acid ester is present in an amount of 1 to 1.5 wt %.

4. The transdermal composition according to claim 1 , wherein said tropisetron is present in an amount of 2.5 to 3.5 wt %.

5. The transdermal composition according to claim 1 , wherein said tropisetron is in the form of its hydrochloride salt.

6. The transdermal composition according to claim 1 , wherein said fatty acid ester is selected from the group consisting of glycerol monolaurate, glycerol monooleate, glycerol monolinoleate, glycerol trilaurate, glycerol trioleate, glycerol tricaprylate, propylene glycol monolaurate, propylene glycol dilaurate, caprylic/capric triglyceride, methyl laurate, methyl caprate, isopropyl myristate, isopropyl palmitate, ethyl oleate and oleyl oleate.

7. The transdermal composition according to claim 6 , wherein said fatty acid ester is glycerol monolaurate.

8. The transdermal composition according to claim 1 , wherein said amide compound is selected from the group consisting of N,N-diethyl-m-toluamide, lauric acid diethanolamide, urea, dimethylformamide and dimethylacetamide.

9. The transdermal composition according to claim 8 , wherein said amide compound is N,N- diethyl-m-toluamide.

10. The transdermal composition according to claim 1 , wherein said composition further comprises a thickener present in the amount of 4 to 5 wt % with reference to 100 wt % of said vehicle.

11. The transdermal composition according to claim 10 , wherein said thickener is hydroxypropyl cellulose with a weight average molecular weight of 800,000 to 1,000,000.

12. A method of transdermally delivering an antivomiting agent to a warm blooded animal comprising administering a transdermal delivering device containing a composition comprising:

(a) a vehicle for transdermal delivery comprising

(i) 25 to 45 wt % of a mixed solution comprising ethanol and propylene glycol,

(ii) a skin penetration enhancer containing 0.5 to 1.5 wt % of a fatty acid ester, and 2 to 5 wt % of an amide compound,

(iii) 50 to 70 wt % of a borate buffer solution; and

(b) 2 to 4 wt %, based on the weight of vehicle, a pharmaceutically acceptable salt of tropisetron as an antivomiting agent, wherein the pH of said composition is within the range of 8 to 9.

13. The method according to claim 12 , wherein said composition has a pH in the range of 8 to 8.5.

14. The transdermal composition according to claim 12 , wherein said fatty acid ester is present in an amount of 1 to 1.5 wt %.

15. The method according to claim 12 , wherein said tropisetron is present in an amount of 2.5 to 3.5 wt %.

16. The method according to claim 12 , wherein said tropisetron is in the form of its hydrochloride salt.

17. The method according to claim 12 , wherein said fatty acid ester is selected from the group consisting of glycerol monolaurate, glycerol monooleate, glycerol monolinoleate, glycerol trilaurate, glycerol trioleate, glycerol tricaprylate, propylene glycol monolaurate, propylene glycol dilaurate, caprylic/capric triglyceride, methyl laurate, methyl caprate, isopropyl myristate, isopropyl palmitate, ethyl oleate and oleyl oleate.

18. The method according to claim 17 , wherein said fatty acid ester is glycerol monolaurate.

19. The method according to claim 12 , wherein said amide compound is selected from the group consisting of N,N-diethyl-m-toluamide, lauric acid diethanolamide, urea, dimethylformamide and dimethylacetamide.

20. The method according to claim 19 , wherein said amide compound is N,N-diethyl-m-toluamide.

21. The method according to claim 12 , wherein said composition further comprises a thickener presented in the amount of 4 to 5 wt % with reference to 100 wt % of said vehicle.

22. The method according to claim 21 , wherein said thickener is hydroxypropyl cellulose with a weight average molecular weight of 800,000 to 1,000,000.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2012
From: SAMYANG CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 027811/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2003
From: PAI, CHAUL MIN; SONG, JIN DEOG; CHO, JOONG WOONG
To: SAMYANG CORPORATION
Reel/Frame 015746/0955 →
Continuity (2)
Continuation In Part 0991308500 · Jan 17, 2002
Related Publication 20040022835A1 · Feb 5, 2004